References
- He Y, Lin J, Kong D, et al. Current state of circulating microRNAs as cancer biomarkers. Clin Chem. 2015;61:1138–1155.
- Zhang J, Song Y, Zhang C, et al. Circulating MiR-16-5p and MiR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer. Theranostics. 2015;5:733–745.
- Yoshie O. Chemokines and chemokine receptors. Nihon Rinsho. 2012;70:212–217.
- Loetscher M, Loetscher P, Brass N, et al. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol. 1998;28:3696–3705.
- Qiu MY, Li JW, Zheng M. The chemokine receptors CXCR4 and CXCR7 in cancer. China Oncol. 2010;20:222–226.
- Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer. 2012;11:74–80.
- Li L, Chen J, Lu ZH, et al. Significance of chemokine receptor CXCR3 expression in breast cancer. Zhonghua Bing li Xue za Zhi. 2011;40:85–88.
- Li K, Zhu Z, Luo J, et al. Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer. Intern J Clin Exp Path. 2015;8:14725–14732.
- Li J, Jin H, Yu H, et al. miRNA‑1284 inhibits cell growth and induces apoptosis of lung cancer cells. Mol Med Rep. 2017; 16:3049–3054.
- Zhang X, Li Y, Qi P, et al. Biology of MiR-17-92 cluster and its progress in lung cancer. Int J Med Sci. 2018;15:1443–1448.
- Pan J, Zhou C, Zhao X, et al. A two-miRNA signature (miR-33a-5p and miR-128-3p) in whole blood as potential biomarker for early diagnosis of lung cancer. Sci Rep. 2018;8:16699.
- Zhu C, Huang Q, Zhu H. Melatonin inhibits the proliferation of gastric cancer cells through regulating the miR-16-5p-Smad3 pathway. DNA Cell Biol. 2018;37:244–252.
- Zhang H, Yang K, Ren T, et al. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3. Cell Death Dis. 2018;9:680.
- Gu Y, Wang XD, Lu JJ, et al. Effect of mir-16 on proliferation and apoptosis in human A549 lung adenocarcinoma cells. Int J Clin Exp Med. 2015;8:3227–3233.
- Ke Y, Zhao W, Xiong J, et al. Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 2013;587:3153–3157.
- Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194:398–405.
- Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207.
- Spaks A. Role of CXC group chemokines in lung cancer development and progression. J Thorac Dis. 2017;9:S164–S171.
- Åsa A, Seok CY, Min H, et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 2009;182:6951–6958.
- Andersson A, Srivastava MK, Harris WM, et al. Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res. 2011;17:3660–3672.